Management expects Q1 2025 revenues of $170 million, with a non-GAAP gross margin of 38% at the midpoint of guidance. Non-GAAP EPS is projected at $0.19, reflecting reduced demand in systems, Flash, ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

A: The integration of patient perspectives is a major driver. Regulatory bodies are drafting new guidance that compels pharmaceutical companies to embed patient voices into trial design, ensuring real ...

Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software ...

SAN FRANCISCO, Jan 16 (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for president-elect Donald Trump and Congress on ...

Pfizer and Intel have sent warnings to the European Chemicals Agency which is considering the move Pfizer pharmaceuticals wrote that a total ban would threaten the viability of this sector.

A team that includes the University of Washington's David Baker, who picked up his Nobel in Stockholm last month, used software tools to design completely new proteins that are able to inhibit ...

Speaking at the 2025 JP Morgan Healthcare Conference, Hoppenot shared plans for the US pharma company to launch four new products in 2025, beginning with its third-line chronic graft-versus-host ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

For Fierce Pharma's day 1 news roundup, click here. Fierce Biotech's day 1 coverage can be found here. Below, check out the latest coverage from day 2, including a wrap-up of the scene outside of ...